Why DiaMedica Therapeutics Inc.’s (DMAC) Stock Is Up 10.01%
As of Wednesday, October 28, DiaMedica Therapeutics Inc.’s DMAC share price has surged by 10.01%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Commentary & Analysis
Why DiaMedica Therapeutics Inc.’s (DMAC) Stock Is Down 5.03%
As of Tuesday, October 27, DiaMedica Therapeutics Inc.’s DMAC share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why DiaMedica Therapeutics Inc.’s (DMAC) Stock Is Up 5.46%
As of Tuesday, October 20, DiaMedica Therapeutics Inc.’s DMAC share price has surged by 5.46%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why DiaMedica Therapeutics Inc.’s (DMAC) Stock Is Up 5.37%
As of Friday, October 09, DiaMedica Therapeutics Inc.’s DMAC share price has surged by 5.37%, which has investors questioning if this is right time to sell.Jenna Brashear
Why DiaMedica Therapeutics Inc.’s (DMAC) Stock Is Up 5.43%
As of Wednesday, September 02, DiaMedica Therapeutics Inc.’s DMAC share price has surged by 5.43%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | DMAC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $513.4 | $241.2 | 38% |
|
| Shares Out (Mil) | 53.9 | 53.4 | 49% |
|
| Institutional Ownership | 30.6% | 92.9% | 13% |
|
| Float (Mil) | 25.3 | 41.2 | 32% |
|
| Beta | 0.97 | 0.96 | 57% |
|
| Avg Daily Volume (000s) | 209 | 486 | 46% |
|
| Price Change (52-week) |
40.2% | 48.4% | 81% |
|
| Growth | DMAC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (21.7%) | (10.1%) | 19% |
|
| EPS (5yr) | 2.3% | 15.8% | 34 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 4.2% | (15.7%) | 67% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.208) | ($0.813) | ($0.748) | |
| Month Ago EPS | ($0.208) | ($0.813) | ($0.808) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.213) | ($0.830) | ($0.880) | |
| Year/Year Chg | 10.6% | 16.6% | 32.7% | |
| Financials | DMAC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($38) | ($44) | 19% |
|
| EPS (TTM) | ($0.716) | ($1.600) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($32) | ($33) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $3 | 46% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $308 | $177 | 30% |
|
| Valuation | DMAC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 13.41 | 2.25 | 93% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | DMAC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (98.2%) | (47.3%) | 6% |
|
| ROE | (114.6%) | (53.3%) | 8% |
|
| Liabilities to Assets | 14.8% | 29.7% | 9% |
|
| F-Score | 2 | 2 | 7% |
|
DiaMedica Therapeutics Inc. did not pass any screens on 10/29/2026.
